Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods
|
|
- Luke Hunter
- 6 years ago
- Views:
Transcription
1 Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods Single-use systems (SUS) offer biopharmaceutical manufacturers significant gains in process flexibility, speed, and efficiency. Implementation of Single-Use Systems and components in biopharmaceutical manufacturing processes has increased rapidly in recent years. SUS are comprised of polymers, and their manufacturing process can utilize a variety of chemical processing aids (i.e. wetting agents, slip agents, plasticizers, antioxidants, blocking agents). In this manner, any polymeric processing component that has product or process fluid contact can contribute chemical entities to the fluid or product. Generally, these entities include oligomers, plasticizers, antioxidants, slip agents, or degradation products. The potential for these entities to be introduced to the product or process fluid is an inherent risk when implementing SUS into biopharmaceutical manufacturing processes. Potential additive entities may be in the form of extractables or leachables. Extractables are organic or inorganic chemical entities that can migrate from a material under aggressive conditions such as elevated temperature, extreme surface exposure, and/or aggressive solvent systems. Leachables are organic or inorganic chemical entities that can migrate from a material under normal processing conditions. Leachables are often, but not always, a subset of extractables. As knowledge about extractables and leachables grows, biopharmaceutical manufacturers and regulatory bodies are taking notice and trying to implement strategies to ensure that appropriate evaluations can be completed to adequately protect patient safety. Presently, there are no specific regulations for extractables testing for SUS. In contrast, there are regulatory guidelines and regulations from FDA (21 CFR ), and EMEA (EMEA/ CVMP/205/04) for leachables in drug product. 21 CFR (a) specifically states that Equipment used in the manufacture of drug product shall be constructed so that surfaces that contact components, in-process materials, or drug products shall not be reactive, additive, or absorptive so as to alter the safety, strength, quality, or purity of the drug product beyond the official or other established requirements. The BioPhorum Operations Group (BPOG) Extractable Work Group is composed of subject matter experts from 20 biopharmaceutical manufacturers. In 2014, the Extractables Work Group established and published a standard protocol for extractables testing of SUS components. The standard extractables protocol provides information on: extractables testing methods, sample preparation, extraction conditions, Kathryn McGohan Scientist I Bristol-Myers Squibb Kathryn McGohan is a Scientist I within the Materials Science group of the Global Manufacturing Sciences & Technology organization at Bristol-Myers Squibb. Kathryn is responsible for the selection, qualification, and validation of single-use products for use in late stage development and commercial biopharmaceutical manufacturing processes (U.S. and ex-u.s.). Kathryn also supports the authorship of CMC regulatory filing sections, new product launches, and continuous improvement efforts. Kathryn currently represents Bristol-Myers Squibb on the BioPhorum Operation Groups (BPOG) Disposables Workstream. and guidance for reporting extractables data. Adoption of the standard extractable protocol by suppliers would ensure that a comprehensive and consistent set of extractables data is available to the end users for assessment. Availability of these data would also benefit suppliers, as it would allow end users to more readily implement new SUS into their manufacturing processes. Another working group has been formed to address the topic of leachables. The BPOG Leachables Work Group is composed of subject matter experts from 22 biopharmaceutical manufacturers. The BPOG Leachables Work Group has been working collaboratively toward developing an industry best practice guide to ensure a robust and streamlined approach to understanding the materials used in the process, their impact on the process, and eventually the API. Regulators and biopharmaceutical manufacturers agree that a risk-based approach to assessing the issue of extractables and leachables is appropriate. Per ICH Q9 guideline, Quality Risk Management offers guidance on Drug Product, It is important to understand that product quality should be maintained throughout the product lifecycle such that the attributes that are important to the quality of the drug (medicinal) product remain consistent with those used in the clinical studies. 6 BioPharma Asia July/August 2016 Augmented Reality powered by Aurasma 4
2
3 Biopharmaceutical manufacturers must assess the various materials used in their respective manufacturing processes. This assessment should begin with a thorough review of the extractables data available for each component. Once the extractables data has been reviewed, further assessment is required to ensure that the components used are compliant with the CFR requirement. Performing an effective assessment requires an understanding of the conditions under which the SUS components will be used in the actual manufacturing process. Consideration must include: Toxicological Risk: Final Drug Product safety Product Quality: Impact on final drug product quality i.e. stability, activity Process Performance: Impact on process performance, i.e. cell growth The regulations and guidelines that are currently in place do not provide details on how to assess risks, how to design a test plan, how to perform analyses, or how to interpret the extractables and leachables profiles. The BPOG leachable work group proposes that a scientific approach be used, whereby process knowledge and experience gained during manufacturing of batch lot(s) during different phases of drug development is leveraged towards a comprehensive process understanding and associated risks. BPOG supports using the principles of risk management / assessment to better identify, evaluate, communicate and mitigate extractables / leachables risks to product quality and patient safety. To this end, the BPOG Leachables team is developing a Leachables Best Practices Guide. This Best Practice Guide is comprised of three main sections described below: The Risk Assessment Model, Leachables Study Design, and Analytical Methods. The Risk Assessment Model: The Risk Assessment Model will guide the user through an assessment which considers various aspects of any polymeric materials used in the drug manufacturing process as well as the conditions under which the SUS are used within the process. The BPOG leachable work group Risk Assessment Model Best Practice guide is aligned with the ICH Q9 guidance on Quality Risk Management (QRM). The QRM guidance indicates that the evaluation of risk to quality should be based on scientific principles and ultimately link to the protection of the patient. The BPOG Risk Assessment model aims to allow for science and risk based assessments of leachables that are built upon a foundation of comprehensive process knowledge, which is key to quality by design principles. The comprehensive process knowledge required include, but is not limited to: understanding of data that has been gathered through Related Product Focus - Finesse Leverage cutting-edge automation and maintain flexibility in system operations The Finesse SmartFactory platform integrates and automates process control, batch automation and data management for your bioprocess facility. SmartFactory features an open architecture that lets you choose the equipment best suited and priced for your unit operations regardless of manufacturer. SmartFactory provides seamless integration and control of vessels and skids from top bioprocessing equipment vendors at a commercial scale. Mix and match equipment or add intelligence to your existing infrastructure to get more out of your facility network. SmartFactory lets you select the level of automation required for each unit operation. You can also focus simultaneously on the compatibility of single-use materials between upstream and downstream for global process yield optimization. And in the case of multi-product facilities, the ability to reconfigure the process train, depending on the campaign of the molecule being produced is extremely important. Process flow can be designed in a modular and scalable manner while maintaining quality and regulatory compliance in electronic batch records at the same time. With a SmartFactory, you leverage cutting-edge automation, enabling you to produce higher yields, significantly reduce labor and capital expenses, and maintain flexibility in your system operations. 8 BioPharma Asia July/August 2016
4 research and development studies, process descriptions, batch records, standard operating procedures, technical reports, data trending, and operating parameters. The BPOG Risk Assessment Model provides key material, process, and operating attributes to consider for Extractable/Leachable assessments. The properties of the solution in contact with the component of interest is a key consideration. Solutions with higher solvation power, such as organic solvents, can increase penetration into polymeric materials, which increases the propensity for leachables to be contributed into the fluid from the component. Based on this, solutions with lower relative solvation power represent a lower risk for leachables. Similarly, higher temperatures and/or longer durations of contact increase the likelihood of leachables to be added. Therefore, processes that occur under high temperatures or over longer periods of time represent a higher risk of leachables than do low temperature or short duration processes. Another important consideration is the volume of solution in contact with the component relative to the solution contact surface area. Solutions that have high volume relative to surface area provide some dilution of potential leachables, reducing the potential for impact as a result of those leachables. Another important risk factor is the distance along the production stream. A leachable compound that is introduced into a process stream prior to purification or clearance steps is less likely to be forward processed and persist into the API. Therefore risk increases from Vial Thaw and Upstream steps through Drug Substance Filling, and up through Drug Product Fill /Finish Steps. Using these key factors, the BPOG leachables team is developing a tool to perform a risk assessment that is quantitative or qualitative, based on the preference of any given individual company. The tool is standardized in that it provides key parameters, but it is also flexible to fit a wide variety of end user quality systems/approaches. Within each attribute, individual companies have the ability to customize the levels of risk and cutoff points, as deemed appropriate based on their process knowledge and risk tolerance. Another important consideration for any extractable or leachable evaluation include: pre-treatment steps, such as autoclaving, gamma irradiation, water for injection or buffer flushes, etc. These pre-treatment steps have the potential to impact the extractable/leachable profile for a given component, and as such should be considered in the overall evaluation. Using the risk assessment model, SUS applications can be ranked into High, Medium, and Low Risk categories. This ranking allows the company performing the assessment to determine whether extractables data is sufficient to support a given SUS application, or whether further evaluation and/or leachables testing will be required. This also allows prioritization of evaluations and leachables studies to ensure that the higher risk applications can be identified and thoroughly evaluated. Leachables Study Design Once a process is well understood, and the SUS applications requiring leachables testing have been identified through use of the risk assessment model, a leachable study will be developed to support the application. The leachable work group Leachable Study Design Best Practice Guide is in development with the goal of providing users with the key parameters to consider when designing a study to ensure robustness and efficiency. A robust study will support the full range of possible manufacturing or storage conditions, which increases overall efficiency. In addition to being robust and efficient, it is important that a study be designed appropriately for the component type and application that will be supported. The Best Practice Guide will provide recommendations for customizing study design based on the type of component (e.g. filter, storage, processing) and application under consideration. With a well thought out study design, a user can design and execute a study once and be able to leverage the results from that study for other similar process steps (technical transfer, similar applications, etc.) where applicable. The Leachable Study Design section will present parameters to consider when designing a study. As a result, an end user can efficiently design a study to support the full range of their manufacturing process conditions to more thoroughly understand the potential leachables that may be present in their in-process streams and products. This will allow maximum value to be garnered from the data generated. Several key design parameters described in the Best Practice Guide are the same as considerations which increase the risk to process. Since contact duration and higher temperatures increase the risk of leachables, the leachables study design should be developed in order to bracket the longest possible duration of contact as well as the highest potential temperature. Also, the guide presents options for studies that will need to be carried out over long periods of time ( 6 Months) to support storage. For example, when designing a long-term study, users should consider interim time points. For each time point, a separate control and test sample should be used in order to mitigate any risk of contaminating a pooled sample during aliquoting. This will also reduce the possibility for inaccurate results due to varying surface area to volume ratios over time due to aliquot removal. Other considerations described in the guide will include: sample handling, i.e. using a scale down approach and developing an appropriate surface area to volume ratio for testing, pretreatment of samples (gamma irradiation or steam sterilization), and appropriate storage of samples as well as control materials. The guide will also provide information on selecting an appropriate solvent for testing. In most cases it is best to select actual process streams/fluids. At times, this not possible due to availability or analytical interference concerns. In these cases, users can use a worst-case solution or other alternate solution and present an appropriate justification for July/August 2016 BioPharma Asia 9
5 that choice. In addition to providing a framework for designing an appropriate and robust leachables study, the Leachables Study Design section of the BPOG Best Practice Guide is intended to provide regulatory agencies with information. The information can be used to bolster the agency s ability to evaluate the strength of data packages which have been provided to them by manufacturers in support of their manufacturing operations. Ultimately, by helping companies to develop appropriate study parameters, and facilitating strong Health Authority evaluation, the Best Practice Guide will benefit patients through an increased assurance of safety. This goal is paramount in the mind of both drug manufacturers, and health authorities. Analytical Methods Once the parameters of the leachable study have been established, users must determine what analytical methods will be used to detect any leachable compounds present in the samples. The leachables work group Analytical Methods Best Practice Guide is in development to provide industry with key considerations that users are able to identify and to assess any leachables detected through a leachables study. The Analytical Method section is designed to provide recommendations to users for the selection of methods, method parameters, and method performance indicators so that the maximum amount of information can be gathered from samples generated through well-designed leachables studies. Enhanced detection, identification, and quantification of leachables will ultimately lead to a better understanding of Single Use Systems and components through availability of more accurate and reliable data. This will allow toxicologists to generate well informed conclusions about the impact anticipated to the patient from the leachables species that may be present in a formulation. The Analytical Methods Best Practice Guide is being developed under the assumption that an acceptable extractable study has been conducted, and therefore information on the potential leachables is available - see BPOG Standard Extractables Protocol for Biopharmaceutical Single Use Systems and Components. Based on the Standard Extractables Protocol, the Analytical Methods Best Practice Guide will recommend a robust approach that includes the use of analytical techniques that can screen for potential unknowns or unexpected entities. The guide also provides options for a more targeted approach to be used when applicable. The main analytical methods recommended are listed for each analyte class, and are not limited to: Organic Volatiles o Headspace Gas Chromatography with Mass Spectrometric o Headspace Gas Chromatography with Flame Ionization Organic Semi-Volatiles o Gas Chromatography with Mass Spectrometric o Gas Chromatography with Flame Ionization Organic Non-Volatiles o Liquid Chromatography with Mass Spectrometric o Liquid Chromatography with Photo Diode Array Inorganic (Trace Elements and Heavy Metals) o Inductively Coupled Plasma Mass Spectrometry o Inductively Coupled Plasma Optical Emission Spectrometry In cases where other techniques have been used in an extractables study, those techniques should be utilized in the leachables study as well. Also, other techniques may be used for leachables studies where applicable and necessary to supplement the data generated through the main analytical techniques. For each analytical method, appropriate internal standards and reference materials are recommended to monitor the performance of the analysis, as well as to establish the level of the determined leachable species. The Analytical Method Best Practice Guide will also provide users with recommendations for instances when a specific compound reference material is not available. In addition to recommending the analytical methods used, the Best Practice Guide will provide users with information to assist in developing appropriate Analytical Evaluation Thresholds (AETs) and Safety Concern Thresholds (SCTs). The SCT can be based on Product Quality Research Institute (PQRI) recommendations proposed for parenteral drug products and accepted for orally inhaled and nasal drug products (Ball D, Blanchard J, Jacopson-Kram D, et al. Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation. Toxicol Sci 2007; 97(2):226-36). Specific recommendations are detailed in the Analytical Method Best Practice Guide. The Best Practice Guide will also provide recommendations for validation of leachable methods where necessary following the ICH Q2 guidelines. Validation of quantitative methods may include the characteristics of: accuracy, precision, specificity, detection limit, quantitation limit, linearity, and range depending on the intended use of the method. Validation of limit test methods may include specificity and detection limit. Furthermore, unexpected compounds observed in the analysis may need to be validated into the method if they reach an established SCT level. Leachables data reporting recommendations will also be described in the Analytical Methods Best Practice Guide. 10 BioPharma Asia July/August 2016
6 The BPOG Leachable Working group suggests summarizing data into a report inclusive of representative chromatograms and raw data tables. Additionally, the report should include analytical conditions for each technique. Specific suggestions for analytical parameters and method performance criteria are also detailed in the Analytical Methods Best Practice Guide. Summary The protection of the safety of our patients is the foremost responsibility of any biopharmaceutical manufacturer. The BPOG Leachables Working Group team has been working collaboratively to develop a Best Practice Guide that provides an end to end strategy for handling the complex issue of Single Use System components and their potential process additives. The Best Practice Guide includes the following three subsections: Risk Assessment Model Leachables Study Design Analytical Methods. Adoption of the BPOG Leachables Best Practices will enable biopharmaceutical manufacturers to develop a customized strategy to perform a risk assessment that enables efficiency through knowledge based prioritization of required work. It will also facilitate development of well-designed and robust leachable studies which rely on appropriate analytical methodologies to detect, identify, and quantify any leachable species present. In turn, this will enable enhanced accuracy and reliability of leachables data. Accurate data supports more precise toxicological understanding of the potential impact of the leachable profile to patient safety, maintaining product quality. The Best Practice Guide will also assist regulatory bodies in assessing the strength of data packages presented by biopharmaceutical manufacturers. This ultimately benefits patients through increased assurance of safety. Acknowledgement This article is based on the work of subject matter experts from 22 BioPhorum Operations Group member companies. The guide - BEST PRACTICES FOR MITIGATING RISK FROM LEACHABLES IN SINGLE-USE SYSTEMS - will be freely available on the BPOG website ( biophorum.com/) when it is published in November Related Product Focus - GE Healthcare Life Sciences Reliable supply, predictable performance GE Healthcare s ReadyToProcess chromatography columns help you plug right into today s challenges. The columns are supplied prepacked and ready for use to simplify and accelerate bioprocessing, reduce time-consuming routines, and ultimately increase your manufacturing agility. With a robust column design and validated packing methods, the columns exhibit high lot-to-lot consistency. ReadyToProcess columns are available with a range of BioProcess chromatography resins in five different sizes. Reliable supply Reliable and predictable supply of manufacturing tools under all circumstances is key to meet your goals. A standardized column format allows off-the-shelf availability of ReadyToProcess columns, for short delivery lead times. As a supplier of both resins and prepacked columns, GE Healthcare takes responsibility for the complete supply chain, from chromatography resin production to the final prepacked ReadyToProcess column. ReadyToProcess columns are covered by our extensive security of supply program for chromatography resins. Predictable performance ReadyToProcess columns are delivered presanitized, prequalified, and ready for use. With a robust design and a validated packing method for each resin, the columns offer a predictable performance. Each individual ReadyToProcess column is qualified by efficiency testing against its validated specifications, and every column is supplied with a certificate of analysis and a customer reference sample. July/August 2016 BioPharma Asia 11
PHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
Evaluating single-use systems
B i o p r o c e s s Validation Extractables and Leachables from Single-Use Disposables Denise Bestwick and Raymond Colton Evaluating single-use systems for extractables and leachables is new territory
Derivation and Justification of Safety Thresholds
Derivation and Justification of Safety Thresholds Douglas J. Ball, MS, DABT Chair, PQRI L&E Toxicology Subgroup Research Fellow, Safety Sciences - Pfizer, Inc. Agenda Basic Definitions Current Regulatory
Extractables and leachables: An Introduction
Extractables and leachables: An Introduction Tim Hulme Smithers Rapra THulme@smithers.com 44(0)1939 252 418 1 Extractables and leachables: An Introduction Tim Hulme Smithers Rapra thulme@smithers.com 2
Driving Value through Innovation in Biotech Manufacturing. Agenda
Driving Value through Innovation in Biotech Manufacturing Jorg Thommes, PhD Senior Vice President Operations Technology and Innovation Biogen 7 October 2015 Agenda Biopharma Legacy, Trends, & Challenges
3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry. Global Expertise delivered locally
3M Purification Inc. Technical and Scientific Services Global Support for the Life Science Industry Global Expertise delivered locally Global expertise delivered locally As a global leader in measuring,
Advancements on implementation of single use technology in vaccine manufacturing
Advancements on implementation of single use technology in vaccine manufacturing October 25 th, 2013 DCVMN Meeting Rio de Janeiro, Brazil Outline Overview of single use products Applications of single
Colorants in Medical Devices:
Colorants in Medical Devices: The Spectrum of Current Regulatory Expectations John Iannone Program Manager/ Technical Specialist Overview» Company Introduction» Why use Colorants in Devices?» Regulatory
BIOPHORUM OPERATIONS GROUP (BPOG) BEST PRACTICES GUIDE FOR EVALUATING LEACHABLES RISK FROM POLYMERIC SINGLE-USE SYSTEMS USED IN BIOPHARMACEUTICAL
BIOPHORUM OPERATIONS GROUP (BPOG) BEST PRACTICES GUIDE FOR EVALUATING LEACHABLES RISK FROM POLYMERIC SINGLE-USE SYSTEMS USED IN BIOPHARMACEUTICAL MANUFACTURING Main Authors Aidan W. Sexton, Ph.D., Senior
Single-Use Final Fill: Benefits and Considerations
Single-Use Final Fill: Benefits and Considerations TENDÊNCIAS DE TECNOLOGIAS DE FABRICAÇÃO E ASSÉPTICA DE MEDICAMENTOS Ana Luísa Lampert Cadore Sales Specialist SU & Aseptic Process Solutions ana.cadore@merckgroup.com
Leachable and Extractable Testing
Leachable and Extractable Testing A Primer on Regulations and Methods As presented to By: Anthony Grilli, MS General Manager SGS LSS NJ Laboratory 973 244 2435 Anthony.Grilli@SGS.com Summary Why perform
Considerations for Ophthalmic Drug Products in Semi-Permeable Packaging
Considerations for Ophthalmic Drug Products in Semi-Permeable Packaging Bausch + Lomb Thresholds and Best Practices for Parenteral and Ophthalmic Drug Products (PODP) February 22-23, 2011 Bethesda 23/02/2011
PRIMARY PACKAGING. Influences the Results of E&L Studies
SCHOTT Pharma Services Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar How Sterilization of PRIMARY PACKAGING Influences the Results of E&L Studies As the demands that are being placed on
Development of next-generation single-use films for optimal performance in biomanufacturing
Development of next-generation single-use films for optimal performance in biomanufacturing Susan Burke, PhD Bioprocess R&D GE Healthcare, Life Sciences Overview Importance of voice of customer in film
Analytical and formulation attributes
Peer reviewed article Analytical and formulation attributes in developing generic sterile injectable liquid and lyophilized drugs (part 1) Arindam Roy ARINDAM ROY 1,2 *, GURMUKH CHANANA 1 *Corresponding
API Testing Requirements to Support the EI Risk Assessment. Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016
API Testing Requirements to Support the EI Risk Assessment Elisabeth Corbett Associate Director, GRS-CMC, Bristol-Myers Squibb November 9, 2016 Agenda Background Review of ICH Q3D Risk Assessment Principles
The biopharmaceutical industry
S i n g l e - U s e APPLICATIONS Understanding Particulates in Single-Use Bags Their Relationship to USP Chapter by Michael W. Johnson The biopharmaceutical industry is facing many challenges. Global
ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit CPMP/ICH/142/95 ICH Topic Q 3 A Impurities Testing Guideline: Impurities in New Drug Substances Step 5 NOTE
VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit CVMP/VICH/591/98-FINAL London, 10 December 1998 VICH Topic GL2 (Validation: Methodology) Step 7 Consensus
BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.
Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities
Single-use technology in downstream unit operations
Single-use technology in downstream unit operations ÄKTA ready chromatography system and more Madhu Raghunathan, Bioprocess capability days, Boston Imagination at work Presentation outline Introduction
Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
14 September 2017 EMA/CHMP/BWP/534898/2008 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the requirements for quality documentation concerning biological investigational medicinal
HISTORY AND MILESTONES
HISTORY AND MILESTONES HISTORY AND MILESTONES DOC S.r.l., Documentation Organization & Consultancy, was established in 1997 by MASCO group C.E.O. Eng. Alberto Borella and Eng. Paolo Curtò who became Managing
ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
Pharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful
Pharma&Biotech ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and
Validation of a concentration assay using Biacore C
GE Healthcare Application Note 48 Biacore systems Validation of a concentration assay using Biacore C Guideline for development of a GxP - compliant concentration assay Support for informed decision-making
Single-Use Products in BioManufacturing: Innovations Driving the Industry Bioprocess International SUPPLEMENT March 2011 By Eric Langer
Single-Use Products in BioManufacturing: Innovations Driving the Industry Bioprocess International SUPPLEMENT March 2011 By Eric Langer Biopharmaceutical manufacturers and CMOs are continuing to integrate
Regulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
Early Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
Agilent solutions for contract research and manufacturing organizations
Agilent solutions for contract research and manufacturing organizations Cooperation between pharmaceutical companies and contract research organizations A successful approach to increasing efficiency along
USP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
CSL s Large Scale Cell Culture Facility
BioProcess Network 20 th October 2011 CSL s Large Scale Cell Culture Facility Tim Hughes Sr. Dir. Clinical Manufacturing CSL Objective How to maximise the opportunity to build a state-of-theart facility
IMPURITIES IN NEW DRUG PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Recommended for
MDI Manufacturing Services
MDI Manufacturing Services Presenter, Date Who we are 3M Drug Delivery Systems is a division of 3M dedicated to working together with pharmaceutical and biotech companies to bring new and improved products
An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen
An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies SPEAKER: Suzanne Murray Biogen Contents 1. BioPhorum Operations Group (BPOG) and the Post-approvals
An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America
An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America SPEAKERS: Janett Mugaburu-Richards, M.S. Pfizer Inc. Kavita Ramalingam Iyer, Ph.D Merck & Co., Inc. Contents
ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
GUIDELINE FOR THE STABILITY TESTING
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 GUIDELINE FOR THE STABILITY TESTING OF NON-PRESCRIPTION (OTC)
Analytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
Application of Quality Risk Management Tools for Cell Therapy Manufacturing
Application of Quality Risk Management Tools for Cell Therapy Manufacturing 17 th ISCT Annual Meeting May 20, 2011 Jean Stanton Associate Director, Product Quality Management Janssen Supply Chain Conflict/Disclaimer
Manufacturing Integrated Biologics Manufacturing
Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Specifications Breakout Session 2 Pete Yehl and Mike Coutant, moderators
Paradigm Change in Manufacturing Operations
Technical Report No. 54-4 Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 3: Case Studies in the Manufacturing of Biotechnological Bulk Drug
Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products.
Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. 3rd FDA/PQRI Conference on Advancing Product Quality March 22-24, 2017 TRACK #2 Achieving Drug Product Quality: Novel
Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology
Technical Overview Method Development and Validation for Online UV-Dissolution Methods Using Fiber-Optic Technology Introduction Online fiber-optic and multicell UV-dissolution systems have become increasingly
Safety Qualification Process and Application of Thresholds. Jim Blanchard PQRI L&E Toxicology Subgroup Principal Scientist Aradigm
Safety Qualification Process and Application of Thresholds Jim Blanchard PQRI L&E Toxicology Subgroup Principal Scientist Aradigm Outline Safety qualification process What to do when leachables exceed:
Clare Simpson 21 st November Content courtesy of Steve Jones, Paul Illot, Bert Frohlich, Thomas Ryll Biopharm Services
Modelling a technology roadmap for acceleration of global industry innovation Presentation to Wales Life Science Hub, Health Economics Special Interest Group Clare Simpson 21 st November 2016 Content courtesy
Filtration of Cell Culture Growth Media and Process Buffers
Customer Application Brief Bioprocess, Biologicals, & Pharmaceutical Filtration of Cell Culture Growth Media and Process Buffers Introduction Media feeds and process buffers are two universal additives
Validation of Sterilizing Grade Filters
Validation of Sterilizing Grade Filters Presented by Laura Okhio-Seaman Sartorius Corporation 1 Sterilizing Grade Filters The definition of a sterilizing grade filter is one that will produce a sterile
Agilent Resources for Workflow Compliance MEASURING ELEMENTAL IMPURITIES IN PHARMACEUTICAL MATERIALS
Agilent Resources for Workflow Compliance MEASURING ELEMENTAL IMPURITIES IN PHARMACEUTICAL MATERIALS AGILENT SOLUTIONS USP / & ICH Q3D Implementing Elemental Impurities Tests in the Pharmaceutical
Scientific Considerations for Continuous API Manufacturing
Scientific Considerations for Continuous API Manufacturing Thomas O Connor, Ph.D. Office of Pharmaceutical Quality/Office of Testing and Research US FDA Center for Drug Evaluation and Research FDA PQRI
Lifecycle Product Quality Risk Management
Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,
ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management
1 2 3 14 December 2017 EMA/CHMP/ICH/804273/2017 Committee for Medicinal Products for Human Use 4 5 6 7 ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle
TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE MANAGEMENT Q12
INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE TECHNICAL AND REGULATORY CONSIDERATIONS FOR PHARMACEUTICAL PRODUCT LIFECYCLE
October 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls
Use in Process Characterization. Nathan McKnight
Scale-down Model Qualification and Use in Process Characterization Nathan McKnight CMC Strategy Forum 28 January, 2013 Outline Slide 2 Introduction and context Scale-down model design and key elements
This article specifically covers incorporation of physical and chemical indicators (PCIDs) into or onto the drug product.
Introduction The pharmaceutical industry is criminalized with circulation of counterfeit drugs risking healthcare and the life of users. This has become quite menacing in recent times with the lure of
Principal approach to CPV :
Principal approach to CPV : Integration with Quality Systems & Operating Mechanisms J. Gampfer, Baxalta, Vienna Austria Baxalta Principal Approach to CPV J. Gampfer Page 1 Baxalta Principal Approach to
Challenges and Opportunities in the Development of integrated Drug Device Combination Products CMC Strategy Forum, Tokyo, 5 December 2017
Challenges and Opportunities in the Development of integrated Drug Device Combination Products CMC Strategy Forum, Tokyo, 5 December 2017 F. Wildenhahn, Human Factors Engineering & U. Grauschopf, Head
PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS VALIDATION
1 Working document QAS/13.527/Rev.2 August 2014 RESTRICTED 2 3 4 5 6 7 8 9 10 PROPOSAL FOR REVISION OF THE SUPPLEMENTARY GUIDELINES ON GOOD MANUFACTURING PRACTICES: VALIDATION, APPENDIX 7:NON-STERILE PROCESS
Improving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns
Improving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns By K. John Morrow, Jr. Ph.D. In the last two decades, the bioprocessing industry has confronted the demands
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
BIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
Guideline on setting specifications for related impurities in antibiotics
1 2 3 4 14 July 2010 EMA/CHMP/CVMP/QWP/199250/2009 Committee for Medicinal Products for Human Use (CHMP) / Committee for Medicinal Products for Veterinary Use (CVMP) 5 6 7 Guideline on setting specifications
Elemental Impurities Regulations View from a CRO
White Paper Elemental Impurities Regulations View from a CRO Author: Alan Cross, Technical Specialist November 2016 1 www.rssl.com Abstract Regulatory control of elemental impurities in pharmaceutical
Documentation requirements for an initial consultation
Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,
PRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
The Opta SFT-D is available as individual device for end-user assembly with TPE tubing and autoclave sterilization.
Fluid Management 259 Connections 260 Flexboy Bags 264 Flexel 3D Bags 276 Palletank 304 Instruments 314 Single-Use Mixing 318 Freeze-Thaw Systems 354 Aseptic Transfer System 380 Configurable Solutions FlexAct
Introduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
Annex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
European Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
Cleaning and Cleaning Validation of API Plant and Equipment
Regulatory Basis: FDA Quality Systems Regulations Reference: FDA CFR - Code of Federal Regulations Title 21 1 Purpose The purpose of this guideline is: To define the requirements for cleaning plant and
Flexboy 2D Pre-designed Solutions for Storage Best Performance, Assurance of Supply and Closure Integrity for All Process Steps
Storage Best Performance, Assurance of Supply and Closure Integrity for All Process Steps 2 Flexboy 2D Pre-designed Solutions Table Please click on the headline to go to the selected topic Digital Selection
Cell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
Challenges of Analytical Method Transfer in the Pharmaceutical Industry
Challenges of Analytical Method Transfer in the Pharmaceutical Industry White Paper Author: Steve Alley, Technical Specialist 1 Contents Introduction 2 Method Transfer Team 3 Identify Methods 4 Gap Analysis
Essentials in Stability Analysis and Expiry Determination
Published in BioPharma International. Essentials in Stability Analysis and Expiry Determination Thomas A. Little Ph.D. 6/12/2013 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland,
icap 7000 Plus Series ICP-OES Streamlined performance and ultra-low ICP-OES detection limits for routine laboratories
icap 7000 Plus Series ICP-OES Streamlined performance and ultra-low ICP-OES detection limits for routine laboratories icap 7000 Plus Series ICP-OES Powerful multi-element performance for routine and research
Industry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
UNIFI: an innovative enabling platform Ken Eglinton Nordic User Training, September 2013
UNIFI: an innovative enabling platform Ken Eglinton Nordic User Training, September 2013 2013 Waters Corporation 1 Waters Laboratory Informatics Product Portfolio MassLynx Mass Spectrometry Software NuGenesis
Identifying and Controlling CPPs and CMAs
March 2018, BioPharm International Publication Identifying and Controlling CPPs and CMAs Thomas A. Little Ph.D. 2/22/2018 President/CEO Thomas A. Little Consulting, BioAssay Sciences 12401 N Wildflower
At Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
At Your ServIce Microbiology Services The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Microbiology Services Optimize your QC lab workflow and ensure regulatory compliance
Biologics. Biologics. The Centre for Process Innovation. From innovation to commercialisation
Biologics Biologics The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The High Value Manufacturing Catapult is
Flexsafe 3D Pre-Designed Solutions for Storage and Shipping Take Your Facility Into The Future
Flexsafe 3D Pre-Designed Solutions for Storage and Shipping Take Your Facility Into The Future 2 Flexsafe 3D Pre-designed Solutions Table Please click on headline to go to the selected page Digital Selection
Management in Pharmaceutical Industry
Master Program Management: Industrial Management Module: Chemistry for Drug Substances Management in Pharmaceutical Industry Prof. Tatsiana Savitskaya Assoc. Prof. Iryna Kimlenka Lectures 5,6 The Key Aspects:
Fusion Analytical Method Validation
Fusion QbD Software System Fusion Analytical Method Validation The Only Software That Has It All! 100% aligned with FDA/ICH Quality by Design (QbD) guidances! Can be used for LC and Non-LC methods (e.g.
COMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS
COMMON DEFICIENCIES IN FINISHED PHARMACEUTICAL PRODUCT (FPP) DOSSIERS Additional guidance for manufacturers This note identifies the most common quality related deficiencies in recently assessed dossiers
Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle Wendy Zwolenski Lambert, CQM/OE, RAC CMC Strategy Forum January 28, 2013 aligns
Current FDA Perspective for Continuous Manufacturing
Current FDA Perspective for Continuous Manufacturing Sau (Larry) Lee, Ph.D. Deputy Director (Acting) & Emerging Technology Team Chair Office of Testing and Research Office of Pharmaceutical Quality US
22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:
QbD Concepts Applied to Qualification and Transfer of Analytical Methods
QbD Concepts Applied to Qualification and Transfer of Analytical Methods CMC Strategy Forum Latin America - 2014 Patrick Swann Senior Director Technical Development QbD = Quality by Design QbD - A systematic
Process Validation Lifecycle Approach: A Return to Science
Process Validation Lifecycle Approach: A Return to Science Hal Baseman, ValSource LLC, PDA Chairman PDA & ISPE Joint New England Chapter Process Validation Event Sep 16, 2015 Woburn, MA Program Summary
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,
GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives
GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives Stephen Miller, Ph.D. CMC-Lead; Office of New Drug Products Office of Pharmaceutical Quality
Vetter Development Service
A unique blend of expertise for clinical manufacturing Vetter Development Service Supporting your compound s success Answers that work 1 Your molecule s future starts here. By the time your new injectable
Cleaning Validation PRODUCT OVERVIEW
PRODUCT OVERVIEW E700 SERIES SUCCESS IN PHARMA Prozess has established itself as a leader in the technically challenging and regulatory complex pharmaceutical sector, and includes 16 of the top 20 global
Supplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan
Supplier Oversight September 2014 PQRI Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Agenda Mylan Background Setting the Stage with a Scenario Current State Thinking Supplier Qualification
Introduction to 21 CFR 11 - Good Electronic Records Management
INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY, BIOLOGY AND CHEMISTRY Review Article Introduction to 21 CFR 11 - Good Electronic Records Management Pal Tapas Kumar* and Maity Subhasis NSHM Knowledge Campus,